Novo Nordisk vs Sanofi (NVO vs SAN.PA)
Novo Nordisk trades at 10.0x earnings vs 24.3x for Sanofi; Sanofi grows sales faster (+15.7% vs +5.6%). Margins, debt and dividend, Nov 2026.
Quick answer
On today's data (November 19, 2026): Novo Nordisk looks cheaper on P/E: 10.0x against 24.3x for Sanofi. Sanofi grows faster: sales +15.7% against +5.6% for Novo Nordisk in the latest quarter. Novo Nordisk has the better net margin: 33.9% against 8.2% for Sanofi.
This is a snapshot of the numbers, not a recommendation to buy or sell.
Your first analysis is free with a free account, no card.
Short answer
On P/E as of November 19, 2026, Sanofi is the more expensive of the two: it trades at 24.3x its annual earnings against 10.0x for Novo Nordisk. Danish drugmaker Novo Nordisk reports two segments: Diabetes and Obesity care, its largest, with insulins and the drugs Ozempic, Rybelsus and Wegovy; and Rare Disease, with treatments for hemophilia and growth disorders. Sanofi is a drugmaker focused on its Biopharma business: specialty medicines for immunology, rare diseases and neurology, led by Dupixent, its top-selling product, plus flu, pediatric and booster vaccines. What helps read that gap: Sanofi sales +15.7% against +5.6% for Novo Nordisk in the latest quarter; net margin 8.2% against 33.9%; net debt for Sanofi: 0.9x EBITDA against 0.5x EBITDA. A higher P/E is not by itself a buy or a sell signal: it is a snapshot of today.
Novo Nordisk (NVO) and Sanofi (SAN.PA) compete in healthcare and pharma. Here are Novo Nordisk and Sanofi side by side with their real figures as of November 19, 2026: what sets them apart, which fits each kind of investor and the most common questions, without telling you whether to buy Novo Nordisk or Sanofi.
Novo Nordisk vs Sanofi: the figures
| Figure | Novo Nordisk | Sanofi |
|---|---|---|
| Share price | $39.43 (November 18, 2026) | €84.08 (November 19, 2026) |
| Market cap | $173.8 billion | €100.9 billion |
| P/E (TTM) | 10.0x | 24.3x |
| Forward P/E | 1.7x | 8.8x |
| Revenue growth (quarter) | +5.6% | +15.7% |
| Net margin (TTM) | 33.9% | 8.2% |
| Net debt / EBITDA | 0.5x | 0.9x |
| Dividend yield | 4.56% | 4.76% |
| Beta | 0.37 | 0.26 |
Novo Nordisk and Sanofi figures from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 19, 2026; N/A means that Novo Nordisk or Sanofi figure is not available, and we never estimate it.
3 key differences between Novo Nordisk and Sanofi
- Valuation: Sanofi trades at 24.3x its annual earnings and Novo Nordisk at 10.0x; the market pays more for each dollar of Sanofi profit, usually because it expects more growth.
- Profitability: for every 100 of sales, Novo Nordisk keeps 33.9 as net profit and Sanofi keeps 8.2.
- Growth: Sanofi grew sales +15.7% year on year in its latest quarter, against +5.6% for Novo Nordisk.
Novo Nordisk or Sanofi: which fits your profile
- If you want growth: Sanofi is growing faster today, with sales +15.7% against +5.6% for Novo Nordisk and also trades on a higher P/E (24.3x against 10.0x). Investors who prioritise growth usually accept more volatility; the P/E only shows what you pay today for each unit of the last 12 months' earnings.
- If you want income (dividends): Sanofi pays the higher dividend relative to its price.
- If you prefer caution: Novo Nordisk has less debt relative to its profit, which usually gives more room in a bad year.
- If price is what matters most to you: Novo Nordisk trades on the lower P/E; check first whether that is an opportunity or a sign of a business that grows less.
Neither Novo Nordisk nor Sanofi wins on everything, and owning both is also an option: spreading money across several companies or an index fund reduces what rides on each one.
Verdict: Novo Nordisk or Sanofi?
Of the 6 comparable figures in the table, Novo Nordisk stands out on 3 (net margin, lower P/E and less debt over EBITDA) and Sanofi stands out on 3 (sales growth, dividend yield and lower volatility (beta)). That does not name a winner between Novo Nordisk and Sanofi: the table is a snapshot of today, not a forecast.
Keep reading free.
Create your free account to continue reading “Novo Nordisk vs Sanofi (NVO vs SAN.PA)”.
No card required
Novo Nordisk vs Sanofi by dimension
Strategy
Novo Nordisk operates in healthcare and pharma and Sanofi in healthcare and pharma, so they only fight for the same customer when the sector overlaps.
Products and AI
Novo Nordisk and Sanofi sell different things: Danish drugmaker Novo Nordisk reports two segments: Diabetes and Obesity care, its largest, with insulins and the drugs Ozempic, Rybelsus and Wegovy; and Rare Disease, with treatments for hemophilia and growth disorders. And for Sanofi: Sanofi is a drugmaker focused on its Biopharma business: specialty medicines for immunology, rare diseases and neurology, led by Dupixent, its top-selling product, plus flu, pediatric and booster vaccines.
Margins
Novo Nordisk is more profitable: it keeps 33.9 of every 100 it sells, against 8.2 for Sanofi.
Valuation
Sanofi trades at the higher P/E (24.3x against 10.0x for Novo Nordisk). A higher P/E is only justified if earnings grow faster.
Risks
Novo Nordisk is the more volatile: beta 0.37 against 0.26 for Sanofi.
Competitors
Other companies investors compare Novo Nordisk and Sanofi with: Vertex, Boston Scientific, Bayer, argenx. Vertex · Boston Scientific · Bayer · argenx
How Novo Nordisk and Sanofi make money
Novo Nordisk (NVO)
Danish drugmaker Novo Nordisk reports two segments: Diabetes and Obesity care, its largest, with insulins and the drugs Ozempic, Rybelsus and Wegovy; and Rare Disease, with treatments for hemophilia and growth disorders. The United States is its biggest market, ahead of Europe, China and the rest of the world. Its ADRs trade in New York. Full Novo Nordisk analysis.
Sanofi (SAN.PA)
Sanofi is a drugmaker focused on its Biopharma business: specialty medicines for immunology, rare diseases and neurology, led by Dupixent, its top-selling product, plus flu, pediatric and booster vaccines. It sells to hospitals, pharmacies and health systems, with the US and Europe as its main markets. Full Sanofi analysis.
Frequently asked questions: Novo Nordisk vs Sanofi
What is the difference between Novo Nordisk and Sanofi?
Danish drugmaker Novo Nordisk reports two segments: Diabetes and Obesity care, its largest, with insulins and the drugs Ozempic, Rybelsus and Wegovy; and Rare Disease, with treatments for hemophilia and growth disorders. Sanofi is a drugmaker focused on its Biopharma business: specialty medicines for immunology, rare diseases and neurology, led by Dupixent, its top-selling product, plus flu, pediatric and booster vaccines. Both are in healthcare and pharma. As of November 19, 2026: P/E 10.0 vs 24.3; net margin 34% vs 8% (Novo Nordisk vs Sanofi).
Is Novo Nordisk or Sanofi the better stock?
Choosing between Novo Nordisk and Sanofi depends on what you are looking for. Sanofi is growing faster right now, and Novo Nordisk trades on the lower P/E. Fintols does not tell you whether to buy Novo Nordisk or Sanofi: it shows you the differences so you can decide.
Which pays a higher dividend, Novo Nordisk or Sanofi?
As of November 19, 2026, Sanofi yields 4.76% and Novo Nordisk yields 4.56%. Also check how much of their profit Novo Nordisk and Sanofi pay out: if it is more than they earn, it cannot last.
Which is more expensive, Novo Nordisk or Sanofi?
On P/E, Sanofi (24.3x) is more expensive than Novo Nordisk (10.0x) as of November 19, 2026. A higher P/E can be justified if earnings grow faster, so compare it with each company's growth in the table.
Which is more profitable, Novo Nordisk or Sanofi?
On net margin, Novo Nordisk (33.9%) keeps more of every 100 it sells than Sanofi (8.2%), as of November 19, 2026.
Which has more debt, Novo Nordisk or Sanofi?
As of November 19, 2026, Sanofi owes 0.9x its EBITDA and Novo Nordisk owes 0.5x its EBITDA (net debt over EBITDA).
Can I own both Novo Nordisk and Sanofi?
Yes. Many people spread their money across several companies, such as Novo Nordisk and Sanofi, or use index funds so they do not depend on just one. If you are starting out, decide how much you want to invest and for how long before buying Novo Nordisk or Sanofi.
To go deeper: Does Novo Nordisk pay a dividend? and Does Sanofi pay a dividend?.
Related comparisons for Novo Nordisk and Sanofi
- Novo Nordisk vs Vertex
- Boston Scientific vs Novo Nordisk
- Novo Nordisk vs Stryker
- Eli Lilly vs Novo Nordisk
More companies like Novo Nordisk and Sanofi: healthcare and pharma stocks. Educational content about Novo Nordisk and Sanofi, not investment advice.
Full analyses: Novo Nordisk and Sanofi. Machine-readable summary: llms.txt.
Your first analysis is free with a free account, no card.
Your own analysis of Novo Nordisk or Sanofi.
Create a free account and run your first full analysis in a minute. No card needed.
- How it makes money
- Valuation scenarios
- What could go wrong
First full analysis free · No card